Understanding the Pathogenesis of Cardiac Complications in Patients with Propionic Acidemia and Exploring Therapeutic Alternatives for Those Who Are Not Eligible or Are Waiting for Liver Transplantation
Authors:
- Evelina MainesEMEvelina Maines
- Michele MorettiMMMichele Moretti
- Nicola VitturiNVNicola Vitturi
- Giorgia GugelmoGGGiorgia Gugelmo
- Ilaria FasanIFIlaria Fasan
- Livia LenziniLivia Lenzini
- Giovanni PiccoliGPGiovanni Piccoli
- Vincenza GragnanielloVGVincenza Gragnaniello
- Arianna MaioranaAMArianna Maiorana
- Massimo SoffiatiMSMassimo Soffiati
- Alberto BurlinaAlberto Burlina
- Roberto FranceschiRoberto Franceschi
Open Access
- 16 April 2023
- journal article
- review article
- Published by MDPI AG in Metabolites
- Vol. 13 (4) , 563
Abstract
The guidelines for the management of patients affected by propionic acidemia (PA) recommend standard cardiac therapy in the presence of cardiac complications. A recent revision questioned the impact of high doses of coenzyme Q10 on cardiac function in patients with cardiomyopathy (CM). Liver transplantation is a therapeutic option for several patients since it may stabilize or reverse CM. Both the patients waiting for liver transplantation and, even more, the ones not eligible for transplant programs urgently need therapies to improve cardiac function. To this aim, the identification of the pathogenetic mechanisms represents a key point. Aims: This review summarizes: (1) the current knowledge of the pathogenetic mechanisms underlying cardiac complications in PA and (2) the available and potential pharmacological options for the prevention or the treatment of cardiac complications in PA. To select articles, we searched the electronic database PubMed using the Mesh terms “propionic acidemia” OR “propionate” AND “cardiomyopathy” OR “Long QT syndrome”. We selected 77 studies, enlightening 12 potential disease-specific or non-disease-specific pathogenetic mechanisms, namely: impaired substrate delivery to TCA cycle and TCA dysfunction, secondary mitochondrial electron transport chain dysfunction and oxidative stress, coenzyme Q10 deficiency, metabolic reprogramming, carnitine deficiency, cardiac excitation–contraction coupling alteration, genetics, epigenetics, microRNAs, micronutrients deficiencies, renin–angiotensin–aldosterone system activation, and increased sympathetic activation. We provide a critical discussion of the related therapeutic options. Current literature supports the involvement of multiple cellular pathways in cardiac complications of PA, indicating the growing complexity of their pathophysiology. Elucidating the mechanisms responsible for such abnormalities is essential to identify therapeutic strategies going beyond the correction of the enzymatic defect rather than engaging the dysregulated mechanisms. Although these approaches are not expected to be resolutive, they may improve the quality of life and slow the disease progression. Available pharmacological options are limited and tested in small cohorts. Indeed, a multicenter approach is mandatory to strengthen the efficacy of therapeutic options.Keywords
Funding Information
- Azienda Provinciale per i Servizi Sanitari (APSS) of Autonomous Province of Trento
This publication has 103 references indexed in Scilit:
- Propionic acidemia: clinical course and outcome in 55 pediatric and adolescent patientsOrphanet Journal of Rare Diseases, 2013
- Functional characterization of novel genotypes and cellular oxidative stress studies in propionic acidemiaJournal of Inherited Metabolic Disease, 2012
- Chronic management and health supervision of individuals with propionic acidemiaMolecular Genetics and Metabolism, 2012
- Riboflavin Alleviates Cardiac Failure in Type I Diabetic CardiomyopathyHeart International, 2011
- Profiling of oxidative stress in patients with inborn errors of metabolismMolecular Genetics and Metabolism, 2009
- Unusual presentation of propionic acidaemia as isolated cardiomyopathyJournal of Inherited Metabolic Disease, 2009
- Role of Oxidative Stress in Cardiac Hypertrophy and RemodelingHypertension, 2007
- Secondary mitochondrial dysfunction in propionic aciduria: a pathogenic role for endogenous mitochondrial toxinsBiochemical Journal, 2006
- Nutrition therapy of organic acidaemias with amino acid‐based formulas: Emphasis on methylmalonic and propionic acidaemiaJournal of Inherited Metabolic Disease, 2005
- Cardiomyopathy in propionic acidaemiaEuropean Journal of Pediatrics, 1993